Ketoconazole HRA® Granted European Marketing Authorisation as an Orphan Drug for the Treatment of Endogenous Cushing’s Syndrome
Landmark recommendation from EMA paves the way for access without prescription to the ellaOne® morning-after pill across Europe in 2015.
HRA Pharma Acquires a Novel Ovarian Cancer Immunotherapy from Pantarhei Bioscience
HRA Pharma Receives European CHMP Positive Opinion for Ketoconazole in the Treatment of Endogenous Cushing’s Syndrome
Effect of weight on efficacy of Emergency Contraceptives...